Nephrology for the Primary Care Provider

---

Chronic kidney disease (CKD) is a common, yet under recognized problem in America.  In the last 5 years, a number of studies have been published describing new therapies to combat CKD and lower the rate of end stage kidney disease.  This presentation will cover these studies regarding SGLT2 inhibitors, mineralocorticoid receptor antagonists, and GLP-1  agonists to name a few. The goal is to provide practical and concise information, such that physician inertia in prescribing these therapies can be overcome.

Learning Objectives

Following the completion of this lecture, the participant will be able to:

1. Discuss the use of SGLT2 inhibitors in CKD
2. Discuss the role of mineral corticoid receptor antagonists in CKD
3. Discuss the role of GLP-1 agonists in CKD
4. Review the relevant labs that need to be check when confronting CKD in the outpatient setting